| Bioactivity | BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1]. |
| Name | BEBT-109 |
| CAS | 2050906-40-4 |
| Formula | C27H32N8O3 |
| Molar Mass | 516.59 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961. |
BEBT-109
CAS: 2050906-40-4 F: C27H32N8O3 W: 516.59
BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.